By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ProNAi Therapeutics, Inc. 

4717 Campus Drive
Suite 1100
Kalamazoo  Michigan  49008  U.S.A.
Phone: 269-372-3289 Fax: 269-544-1079


Company News
ProNAi Therapeutics, Inc. To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/13/2015 9:32:05 AM
ProNAi Therapeutics, Inc. Initiates Phase 2 Trial Of PNT2258 In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) 1/7/2015 8:49:54 AM
Marina Biotech, Inc. (MRNA) Reports That Licensee ProNAi Therapeutics, Inc. Presented Interim Phase 2 Data On Its BCL2-Targeting DNAi® Therapeutic At American Society of Hematology 2014 12/10/2014 11:25:37 AM
ProNAi Therapeutics, Inc. Reports Significant Activity And Ongoing Durable Responses In Relapsed Or Refractory Non-Hodgkin's Lymphoma With PNT2258 12/5/2014 12:26:15 PM
ProNAi Therapeutics, Inc. Strengthens Senior Management Team To Advance DNAiĀ®-based Oncology Therapeutics 10/22/2014 7:43:27 AM
ProNAi Therapeutics, Inc. Names New President And Chief Executive Officer 9/3/2014 9:03:12 AM
ProNAi Therapeutics, Inc. Banks $59.5 Million Series D To Fund Non-Hodgkin's Lymphoma Studies 4/21/2014 4:22:07 PM
ProNAi Therapeutics, Inc. Secures $12 Million Series C Financing To Expand Phase II Cancer Studies For PNT2258, A Novel BCL2 Inhibitor, In Defined Lymphoma Patients 1/13/2014 8:17:05 AM
ProNAi Therapeutics, Inc. Reports Anti-Tumor Activity From Ongoing Phase II Clinical Study Of PNT2258, A Novel BCL2-Inhibitor, At American Society of Hematology Annual Meeting 12/10/2013 7:03:32 AM
ProNAi Therapeutics, Inc. to Present Phase II Clinical Data at American Society of Hematology for PNT2258, a BCL2 Targeted Drug 11/8/2013 7:52:07 AM